Soft drug design: General principles and recent applications

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.

Original languageEnglish
Pages (from-to)58-101
Number of pages44
JournalMedicinal Research Reviews
Volume20
Issue number1
DOIs
StatePublished - Jan 14 2000
Externally publishedYes

Fingerprint

Drug Design
Pharmaceutical Preparations
Metabolism
Cholinergic Antagonists
Therapeutic Uses
Angiotensin-Converting Enzyme Inhibitors
Adrenal Cortex Hormones
Pharmacodynamics
Pharmacokinetics
Molecules
Metabolites
Therapeutics

Keywords

  • Ester hydrolysis
  • Loteprednol etabonate
  • Metabolism
  • Soft β-blockers
  • Soft drugs

ASJC Scopus subject areas

  • Organic Chemistry
  • Pharmacology
  • Medicine(all)

Cite this

Soft drug design : General principles and recent applications. / Bodor, Nicholas; Buchwald, Peter.

In: Medicinal Research Reviews, Vol. 20, No. 1, 14.01.2000, p. 58-101.

Research output: Contribution to journalArticle

@article{b580b4bfb4c24dbca118b30b179890ea,
title = "Soft drug design: General principles and recent applications",
abstract = "Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.",
keywords = "Ester hydrolysis, Loteprednol etabonate, Metabolism, Soft β-blockers, Soft drugs",
author = "Nicholas Bodor and Peter Buchwald",
year = "2000",
month = "1",
day = "14",
doi = "10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X",
language = "English",
volume = "20",
pages = "58--101",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Soft drug design

T2 - General principles and recent applications

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2000/1/14

Y1 - 2000/1/14

N2 - Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.

AB - Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.

KW - Ester hydrolysis

KW - Loteprednol etabonate

KW - Metabolism

KW - Soft β-blockers

KW - Soft drugs

UR - http://www.scopus.com/inward/record.url?scp=0033966357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033966357&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X

DO - 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X

M3 - Article

C2 - 10608921

AN - SCOPUS:0033966357

VL - 20

SP - 58

EP - 101

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 1

ER -